Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698163 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL7406800 | 0.98 | ALDH1A1 (0.54) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL7406797 | 0.98 | ALDH1A1 (0.54) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL25386615 | 0.93 | POLB (0.56) | ALDH1A1HSD17B10POLBKMT2AMME | |
| SCHEMBL7299545 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL4529791 | 0.84 | POLB (0.49) | ALDH1A1HSD17B10POLBKMT2AMME | |
| SCHEMBL4529797 | 0.84 | POLB (0.49) | ALDH1A1HSD17B10POLBKMT2AMME | |
| SCHEMBL6753269 | 0.84 | KMT2A (0.55) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL6753268 | 0.84 | KMT2A (0.55) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL6622791 | 0.84 | ATM (0.44) | ALDH1A1HSD17B10POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | ALDH1A1 423/4885HSD17B10 2357/4885POLB 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.